Sandoz recently announced a $275 million settlement with its subsidiary Fougera Pharmaceuticals, to resolve allegations of ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

UBS analyst Harry Sephton downgraded Sandoz (SDZNY) to Neutral from Buy with a price target of CHF 44, up from CHF 39.50. The firm cites ...

Generic and biosimilar drug producer Sandoz has agreed a $265 million settlement that aims to put allegations of price-fixing brought in a Pennsylvania lawsuit behind it. The agreement – which ...

Sandoz completed its long-heralded separation from Novartis on schedule this morning, with its shares trading at CHF 24 on the SIX Swiss Exchange. That valued the newly independent company at CHF ...

Strong first year as standalone company; global leader Sandoz uniquely positioned in attractive and growing USD 200 billion market for generics and biosimilars Leading in home market Europe ...

RBC Sandoz Group AG Sponsored ADR (SDZNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). Sandoz Group AG ...

UBS forecasts that Sandoz will likely achieve the lower end of its 24-26% core EBITDA margin target by 2028. To reach the ...

(RTTNews) - Swiss generic pharmaceutical company Sandoz Group AG (SDZNY) announced on Monday that Peter Stenico has been appointed as the new President Region International and member of the ...